← All tasks
Task H-002 · Type H — Insufficient evidence (should abstain)
Does avalglucosidase alfa show superior efficacy over alglucosidase alfa in Pompe disease based on head-to-head trial evidence?
Difficulty
medium
Rarity stratum
sparse
Evidence type
insufficient_evidence
MONDO ID
MONDO:0009290
Curator notes
VERIFIED by full-text grep (2026-09-07): "avalglucosidase" does not appear in the 22 glycogen storage disease II (Pompe) documents in this corpus version. Corpus discusses enzyme replacement therapy generally but not this specific comparison.
Generation outcome
Abstained
No
Abstention correct
No
Gold in retrieved
n/a (no gold docs)
Generation cost
$0.000355
Claims
1
Supported
1
Contradicted
0
Unverifiable
0
Gold documents (0)
No gold documents — this is an insufficient-evidence (Type H) task; the correct answer is abstention.
Retrieved documents (6)
- Pompe Disease: From a Cardiovascular Lens.pubmed:42596035
- Late-Onset Glycogen Storage Disease Type II (Pompe's Disease) with a Novel Mutation: A Malaysian Experience.pubmed:25093132
- Pompe's disease.pubmed:18929906
- Lysosomal storage diseases.pubmed:29152458
- Pompe Disease: a Clinical, Diagnostic, and Therapeutic Overview.pubmed:36969713
- Efficacy and Safety of a Krabbe Disease Gene Therapy.pubmed:35333110
Generated claims (1)
supportedconfidence 0.95
Head-to-head trials have not shown avalglucosidase alfa to be superior to alglucosidase alfa in the treatment of Pompe disease.
pubmed:36969713